[Advances in the study of nitric oxide-donating drugs]

Yao Xue Xue Bao. 2009 Nov;44(11):1200-10.
[Article in Chinese]

Abstract

Nitric oxide (NO) as a messenger and/or effector plays important roles in vivo. The decreased availability of NO or dysfunction in NO signaling has often been implicated in the development and progression of diseases, and design and research of NO-donating drugs has become one of the important strategies in drug discovery. In connection with authors' scientific practice, this article reviews the recent advances in the research of NO-donating drugs.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Aspirin / analogs & derivatives
  • Aspirin / pharmacology
  • Aspirin / therapeutic use
  • Azo Compounds / pharmacology
  • Cardiovascular Diseases / drug therapy*
  • Cell Line, Tumor
  • Drug Design
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / pathology
  • Nitrates / pharmacology
  • Nitrates / therapeutic use
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / pharmacology*
  • Nitric Oxide Donors / therapeutic use
  • Piperazines / pharmacology
  • Signal Transduction / drug effects

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents
  • Azo Compounds
  • N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester
  • Nitrates
  • Nitric Oxide Donors
  • O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate
  • Piperazines
  • Nitric Oxide
  • Aspirin